



REQUEST FOR PROPOSAL

Investigator-sponsored trials

Investigator-sponsored trials (IST) are clinical or non-clinical research studies or trials initiated, sponsored and managed by researchers who are not directly affiliated with a manufacturer.

Blueprint Medicines Corporation is committed to supporting ISTs that contribute to the scientific and medical understanding of our products and relevant disease areas in order to enhance the practice of medicine and ultimately improve patient care.

All IST submissions will be critically reviewed, and a decision will be made based on scientific merit, feasibility, and our current research objectives and available resources. Proposals that directly compete with our current and/or future studies will not be considered.

Important dates

Call for RFP – July 1, 2021

Submission deadline – August 30, 2021

Questions and submissions

EMAIL

grants@blueprintmedicines.com

EXPECTATIONS

Submission must include:

- A full protocol, including the nature and scope of the support requested;
- A curriculum vitae (CV) or resume that documents previous clinical research experience of the proposed investigator(s) and other key research staff;
- Complete Blueprint project budget template, including itemization of costs, services and institutional fees; and
- Proposed study timelines and milestones, including a description of anticipated post-study activities and publications.

A blind evaluation will be completed for all submitted protocols. Protocols will be scored based on six (6) criteria.

- Alignment with areas of interest
- Scientific merit
- Contribution to the understanding of our products and/or relevant disease area
- Feasibility
- Budget
- Research completion timelines

Funding will be provided over a period of 24 months and will be milestone-based. At the conclusion of the study, the final study report and draft manuscript for submission to a peer-reviewed journal must be produced.

AREAS OF INTEREST

Projects that will be considered for Blueprint Medicines support will focus on the following areas:

- Biology of advanced systemic mastocytosis (SM) including molecular and histopathologic evaluation of advanced SM subtypes and correlation of underlying biology with clinical signs and symptoms
- Utilize retrospective data or banked tissue sample analyses to better characterize the diagnostic journey of SM patients and explore potential areas leading to the misdiagnosis of advanced SM

NEXT STEPS

If interested:

Email grants@blueprintmedicines.com to request a Confidential Disclosure Agreement (CDA) and copy of the Investigator Brochure.

To apply:

Email completed submission to grants@blueprintmedicines.com

Approval notification:

All submissions will be reviewed by the Scientific Review Committee, and those selected will be notified by September 30, 2021.

Additional information:

If interested in speaking with a Medical Affairs Representative, please email medinfo@blueprintmedicines.com.